Kaposi Sarcoma in case of solid organ transplantation

Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environ­mental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.

 

 

    Related Conference of Kaposi Sarcoma in case of solid organ transplantation

    October 21-22, 2019

    23rd European Biotechnology Congress

    Zurich, Switzerland
    November 26-27, 2019

    International Conference On Genomics and Molecular Biology

    Lisbon | Portugal
    November 26-27, 2019

    International Conference on Cell and Gene Therapy

    | Lisbon, Portugal
    February 24-25, 2020

    24th Global Congress on Biotechnology

    London, UK
    March 16-17, 2020 |

    12th World Congress and Expo on Cell & Stem Cell Research

    Chicago, Illinois, USA

    Kaposi Sarcoma in case of solid organ transplantation Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in